The estimated Net Worth of Terrance Mcguire is at least $62.8 Milion dollars as of 11 September 2023. Mr. Mcguire owns over 500,000 units of Cyclerion Therapeutics stock worth over $32,615,720 and over the last 13 years he sold CYCN stock worth over $29,994,234. In addition, he makes $159,210 as Independent Director at Cyclerion Therapeutics.
Terrance has made over 11 trades of the Cyclerion Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 500,000 units of CYCN stock worth $3,000,000 on 11 September 2023.
The largest trade he's ever made was buying 626,117 units of Cyclerion Therapeutics stock on 8 April 2019 worth over $10,017,872. On average, Terrance trades about 30,157 units every 42 days since 2011. As of 11 September 2023 he still owns at least 10,853,817 units of Cyclerion Therapeutics stock.
You can see the complete history of Mr. Mcguire stock trades at the bottom of the page.
Terrance G. McGuire serves as Independent Director of the Company. He has served as a member of our Board of Directors since we commenced operations as an independent company in April 2019. Mr. McGuire was a co-founder and is currently a general partner of Polaris Partners. Prior to starting Polaris Partners in 1996, Mr. McGuire spent seven years at Burr, Egan, Deleage & Co., investing in early stage medical and information technology companies. He serves on the board of directors of several private companies and has served on the boards of Acceleron Pharma, Inc., Arsanis, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire is the former chairman of the National Venture Capital Association, which represents ninety percent of the venture capitalists in the U.S., chairman of the board of the Thayer School of Engineering at Dartmouth College, and a member of the boards of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and The Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire earned a B.S. in physics and economics from Hobart College, an M.S. in engineering from The Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School.
As the Independent Director of Cyclerion Therapeutics, the total compensation of Terrance McGuire at Cyclerion Therapeutics is $159,210. There are 4 executives at Cyclerion Therapeutics getting paid more, with Andreas Busch having the highest compensation of $3,251,110.
Terrance McGuire is 64, he's been the Independent Director of Cyclerion Therapeutics since 2019. There are 4 older and 10 younger executives at Cyclerion Therapeutics. The oldest executive at Cyclerion Therapeutics, Inc. is George Conrades, 81, who is the Independent Director.
Terrance's mailing address filed with the SEC is C/O SEER, INC., 3800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie oraz Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics executives and other stock owners filed with the SEC include: